TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8866384
Drug: Ampicillin/sulbactam (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin/sulbactam (2.0 g ampicillin + 1.0 g sulbactam every six hours)
Study: 8866384
Drug: Clindamycin/gentamicin (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin/gentamicin (900 mg clindamycin + 1.5 mg/kg gentamicin every eight hours)
Study: 1727614
Drug: Prednisone and
Normalized name: chloroprednisone and antiinfectives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone and short-term oral cyclophosphamide
Study: 6373007
Drug: Hydrocortisone valerate
Normalized name: Hydrocortisone Valerate
DrugBank: Hydrocortisone valerate (DB14544)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone valerate 0.2% ointment
Study: 30415934
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of direct oral anticoagulants (DOACs) within 3-5 days after ischaemic stroke.
Study: 30415934
Drug: Later initiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Later initiation of direct oral anticoagulants (DOACs) after >7 days or >14 days post-stroke.
Study: 12460222
Drug: Information about
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information about benefits of tests and treatment
Study: 2646729
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous methylprednisolone (IVMP) pulse therapy (1 gm) for group 1 (one or two courses) and repeated pulses for group 2 (four to 21 months)
Study: 25733500
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 to 20 mg/ml for 5 to 7 days)
Study: 25733500
Drug: Azithromycin (5-μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (5-μg disk)
Study: 25733500
Drug: Azithromycin MIC
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin MIC of ≤ 16 μg/ml or disk inhibition zone size of ≥ 13 mm
Study: 23835341
Drug: TNF‐α infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF‐α infusion
Study: 15193831
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg/die)
Study: 2881825
Drug: Somatostatin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (250 micrograms initially as an intravenous bolus and then 250 micrograms/h via infusion)
Study: 29514706
Drug: ASCTAug (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASCTAug (high-dose melphalan with ixazomib)
Study: 29514706
Drug: ASCTCon (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASCTCon (high-dose melphalan)
Study: 22377973
Drug: Gastroretentive ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastroretentive ER formulation with immediate release component (IR/ER)
Study: 22377973
Drug: Gastroretentive ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastroretentive ER formulation without immediate release component (ER)
Study: 22377973
Drug: Conventional ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ER tablet (C-ER)
Study: 17585027
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg) capsules daily
Study: 15253389
Drug: History of
Normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: History of contact with an active leprosy patient and irregular treatment
Study: 10955437
Drug: Oestriol pessaries
Normalized name: Oestriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestriol pessaries 0.5 mg every second day for 24 weeks
Study: 3973310
Drug: Food challenges
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food challenges (71 challenges with doses ranging from 5 to 100 gm)
Study: 3973310
Drug: Placebo (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (12 placebos administered)
Study: 3543241
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (FAC: fluorouracil, doxorubicin, cyclophosphamide) in a protected environment with prophylactic antibiotics
Study: 3543241
Drug: Standard hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hospital room treatment
Study: 16502116
Drug: antithyroid drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: antithyroid drug only
Study: 3541963
Drug: Mesotrin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesotrin (2.5 mg/kg)
Study: 31914685
Drug: 12-week exercise
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week exercise training (aerobic exercise or combination of aerobic exercise and resistance training)
Study: 27977757
Drug: DHA plus
Normalized name: PNV-DHA Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA plus vitamin D (500 mg DHA and 800 IU vitamin D daily)
Study: 23002493
Drug: Patients administered
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients administered a selective serotonin reuptake inhibitor
Study: 23002493
Drug: Patients administered
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients administered two antipsychotic agents
Study: 23002493
Drug: Patients administered
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients administered an opiate
Study: 23002493
Drug: Patients administered
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients administered a diuretic non-antihypertensive agent
Study: 15942629
Drug: ILF (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: ILF (irinotecan plus high-dose 5-fluorouracil and leucovorin)
Study: 10362612
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of rhGH (10.0 and 20.0 micrograms/kg)
Study: 7566950
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (nitroglycerin, calcium channel blocker or both)
Study: 1982983
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg BCH 069 by intravenous injection for 6 weeks 3 times weekly
Study: 1982983
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg BCH 069 by subcutaneous injection for 4 weeks 3 times weekly
Study: 20227123
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation based on PSA-level groupings
Study: 20227123
Drug: High-dose radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radiotherapy
Study: 17513327
Drug: Benazepril 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 0.2 mg/kg per day (ACE-I)
Study: 15727682
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein supplementation (25 g protein and 60 mg isoflavones)
Study: 7515999
Drug: Urapidil (35‐50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (35‐50 mg, n = 10)
Study: 7515999
Drug: Diltiazem (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (25 mg, n = 10)
Study: 2648447
Drug: Viloxazine (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine (an antidepressant)
Study: 27603398
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg pregabalin orally administered 2 hours before surgery
Study: 27603398
Drug: Placebo orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally administered 2 hours before surgery
Study: 24687509
Drug: Primaquine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 30 mg (base)
Study: 24687509
Drug: Chloroquine 600
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine 600 mg (base)
Study: 22676397
Drug: Preladenant (5-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preladenant (5-200 mg single doses)
Study: 22676397
Drug: Preladenant (10-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preladenant (10-200 mg once daily for 10 days)
Study: 16385906
Drug: Chemotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy treatment A
Study: 16385906
Drug: Chemotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy treatment B
Study: 12585165
Drug: Puerarin 500
Normalized name: PUERARIA MIRIFICA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puerarin 500 mg once a day for 3 weeks
Study: 9105229
Drug: 0.015-0.32 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.015-0.32 g/kg 5% rHb1.1 (n = 34)
Study: 2029982
Drug: Kava Extract
Normalized name: Kava extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kava Extract WS 1490 (3 X 100 mg/day)
Study: 28420440
Drug: AHSCT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: AHSCT treatment
Study: 28420440
Drug: Insulin-only treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-only treatment
Study: 15303783
Drug: Desonide (cream,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desonide (cream, ointment, or lotion formulation)
Study: 10553820
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) 40 ppm
Study: 7872445
Drug: Ceftriaxone, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone, 2 g/day for adults and 50 mg/kg/day for children, intravenously once a day for three days
Study: 7872445
Drug: Chloramphenicol, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol, 60 mg/kg/day orally four times a day until defervescence, followed by 40 mg/kg/day for a total of 14 days
Study: 1982289
Drug: Voluntary plane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voluntary plane flights in the two months following treatment
Study: 31451913
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate 2 g daily + 1000 mg calcium + 800 IU vitamin D (strontium group; SG)
Study: 31451913
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg calcium + 800 IU vitamin D (placebo group; PG)
Study: 25959549
Drug: Group cognitive-behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioral therapy (CBT) for BED
Study: 24147266
Drug: Aspirin continued
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin continued (Group 1)
Study: 24147266
Drug: Aspirin stopped
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin stopped (Group 2)
Study: 24147266
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin (Group 3 - Control)
Study: 21319007
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE) 0.625 mg/day and medroxyprogesterone acetate (MPA) 2.5 mg/day
Study: 17245174
Drug: Fenofibrate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (5 mg/kg)
Study: 10197141
Drug: Cetirizine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (20 mg, twice the daily recommended dose)
Study: 9223914
Drug: Interferon-alpha therapy
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha therapy (3 x 10(6) U recombinant IFN alpha, subcutaneously three times a week, every other day, for a total of 12 doses)
Study: 1203699
Drug: Hypertonic glucose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic glucose, fructose, and sorbitol solutions (IV)
Study: 31838497
Drug: TE (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: TE (0.1 mg/day) + IMP (200 mg/day for 12 days)
Study: 29319063
Drug: Supervised Toothbrushing
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supervised Toothbrushing (STB) in Ultra-Conservative Treatment (UCT)
Study: 29319063
Drug: Conventional Restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Restorative Treatment (CRT) with Unsupervised Toothbrushing (USTB)
Study: 29319063
Drug: Atraumatic Restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic Restorative Treatment (ART) with Unsupervised Toothbrushing (USTB)
Study: 29319063
Drug: No-treatment with
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment with Unsupervised Toothbrushing (USTB)
Study: 22187767
Drug: palanosetron (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: palanosetron (0.25 mg) IV
Study: 22187767
Drug: granisetron (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: granisetron (3.0 mg) IV
Study: 22187767
Drug: ondansetron (8.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (8.0 mg) IV
Study: 14998843
Drug: Single-agent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent chemotherapy (gemcitabine, vinorelbine, taxanes)
Study: 14998843
Drug: Carboplatin-based or
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin-based or low-dose cisplatin-based doublets
Study: 14998843
Drug: New biological
Approvals — FDA: no, EMA: no, PMDA: no
Description: New biological agents
Study: 12579942
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution of salbutamol
Study: 8314287
Drug: Cefuroxime (4.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (4.05 g/die)
Study: 8314287
Drug: Cefotiam (5.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotiam (5.30 g/die)
Study: 8314287
Drug: Cefotiam with
Normalized name: cefotiam
DrugBank: Cefotiam (DB00229)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotiam with furosemide (0.5 mg/kg body weight) intravenously
Study: 8314287
Drug: Cefuroxime with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime with furosemide (0.5 mg/kg body weight) intravenously
Study: 3285835
Drug: furosemide (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: furosemide (60 mg)
Study: 29141548
Drug: Cognitive Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Training (CT) program, conducted twice a week for six months.
Study: 28766500
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of memantine 10 mg
Study: 28766500
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of memantine 10 mg
Study: 19794994
Drug: Epidural PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural PCA (ropivacaine 0.2% + fentanyl 5 microg/mL at 4 mL/hr)
Study: 19794994
Drug: IV PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV PCA (ketorolac 0.2 mg/kg + fentanyl 15 microg/mL at 1 mL/hr)
Study: 16874871
Drug: B-OAzM (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-OAzM (omeprazole 20 mg, bismuth subcitrate 240 mg, azithromycin 250 mg, and metronidazole 500 mg, all twice daily for 1-wk)
Study: 16874871
Drug: B-OAM (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-OAM (omeprazole 20 mg, bismuth subcitrate 240 mg, amoxicillin 1 g, and metronidazole 500 mg, all twice daily for 2-wk)
Study: 12775734
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg (intermittent)
Study: 12775734
Drug: Gefitinib 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 500 mg (intermittent)
Study: 12775734
Drug: Gefitinib 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 500 mg (continuous)
Study: 12775734
Drug: Chemotherapy (carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (carboplatin and paclitaxel)
Study: 10835489
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 1000 mg/day
Study: 10835489
Drug: High-dose beta-carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose beta-carotene
Study: 10835489
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg beta-carotene, 0 mg vitamin C)
Study: 10835489
Drug: Beta-carotene 3
Normalized name: beta-carotene 30 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene 3 mg/day
Study: 9353803
Drug: Functional electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional electrical stimulation (twice-daily treatment sessions for 3 months)
Study: 9353803
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily retention of the control probe)
Study: 8384170
Drug: Dexfenfluramine (dFE:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine (dFE: 30 mg per os)
Study: 3885152
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E treatment (mean serum level 5.1 mg/dL)
Study: 25543610
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (loading and unloading mini-implants)
Study: 23062766
Drug: 180 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 μg/d MK-7 supplementation
Study: 23062766
Drug: 360 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 μg/d MK-7 supplementation
Study: 23062766
Drug: MK-7 supplementation
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-7 supplementation (both doses)
Study: 12456604
Drug: Post GnRH
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post GnRH agonist rise in FSH and LH levels
Study: 10479120
Drug: CMV gB
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV gB vaccine with MF59
Study: 10479120
Drug: CMV gB
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV gB vaccine with alum
Study: 10479120
Drug: CMV gB
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV gB vaccine with MF59 (fourth dose)
Study: 8955652
Drug: Topotecan (TPT)
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan (TPT) administered as a 30-minute infusion daily for 5 days, with doses of 0.75 mg/m2, 1 mg/m2, and 0.75 mg/m2 in combination with cisplatin (CDDP) at doses of 50 mg/m2 and 75 mg/m2.
Study: 8955652
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) administered either before TPT on day 1 or after TPT on day 5.
Study: 6309730
Drug: Ampicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (500 mg, single dose)
Study: 6309730
Drug: Cefaclor (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (500 mg, single dose)
Study: 27070434
Drug: Gabapentin (300-2700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (300-2700 mg daily)
Study: 25093663
Drug: Ultrasound-guided Transversus
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided Transversus Abdominis Plane (TAP) block (levobupivacaine = 150 mg)
Study: 25093663
Drug: Continuous Wound
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Wound Infusion (CWI) (levobupivacaine = 150 mg first day and 12.5 mg/h thereafter)
Study: 22928872
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (three weekly physical exercise sessions lasting 60-75 minutes each for 16 weeks)
Study: 20071838
Drug: Lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1% infiltration (20 ml)
Study: 8584192
Drug: Fentanyl 0.005
Normalized name: fentanyl 0.005 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.005 mg/kg + Midazolam 0.2 mg/kg
Study: 8584192
Drug: Fentanyl 0.005
Normalized name: fentanyl 0.005 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.005 mg/kg + Propofol 2.5 mg/kg
Study: 8584192
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg/kg + Propofol 2.0 mg/kg
Study: 31537562
Drug: Treatment-related complications
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-related complications
Study: 25890211
Drug: Rupatadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine (10 mg, 20 mg, 40 mg single doses; 10 mg multiple doses)
Study: 22314633
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (CHM) 5 g twice daily, n = 22
Study: 22314633
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus CHM (Kun Bao Wan) 5 g twice daily plus sessions of acupuncture, n = 20
Study: 22314633
Drug: Hormone therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy, n = 15
Study: 19032447
Drug: Ranitidine hydrochloride
Normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine hydrochloride (300 mg/day)
Study: 19032447
Drug: Rabeprazole sodium
Normalized name: Rabeprazole Sodium
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole sodium (20 mg/day)
Study: 12604982
Drug: Lactobacillus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus GG (LGG) 10^9 orally twice daily for 21 days in infants <1500 g
Study: 12604982
Drug: Lactobacillus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus GG (LGG) for 8 days in infants 1500 to 1999 g